T-Neuro Pharma Announces Publication of Groundbreaking Alzheimer’s Research in Prestigious Journal
ALBUQUERQUE, New Mexico — T-Neuro Pharma, a leading biotechnology company dedicated to developing innovative diagnostics and therapeutics for neurodegenerative diseases, announced the publication of a landmark research article in Proceedings of the National Academy of Sciences(PNAS), a peer-reviewed journal of the National Academy of Sciences….
CEO Making Strides in the Diagnosis of Alzheimer’s Disease Named One of the Three Fellows for LANL’S Prestigious “LEEP” Program
Albuquerque, NM – Los Alamos National Laboratory recently launched the New Mexico Lab-Embedded Entrepreneur Program (New Mexico LEEP) in January of 2022. Through this program, entrepreneurs are provided a two-year fellowship that focuses on technical solutions to society’s largest concerns. These solutions, also referred to as…
T-Neuro Pharma takes a new approach to Alzheimer’s Disease diagnosis and treatment
ALBUQUERQUE — While the vast majority of Alzheimer’s Disease (AD) clinical trials have focused on decreasing beta-amyloid (the sticky protein fragment that gums up the brain and kills its cells) 99.6% of these trials have failed. The 0.4% that succeeded only treat symptoms, but do…